Skip to main content
. Author manuscript; available in PMC: 2022 Dec 12.
Published in final edited form as: Cancer Res Commun. 2022 Nov 3;2(11):1334–1343. doi: 10.1158/2767-9764.CRC-22-0172

Figure 4.

Figure 4.

Duloxetine does not alter uptake and antitumor properties of oxaliplatin. A, Influence of duloxetine (1 or 10 μM) on the intracellular accumulation of oxaliplatin in colorectal cancer cell lines in vitro. B-F, Influence of duloxetine pre-treatment on oxaliplatin-related body weight loss (B), tumor volume of xenografted luciferase-expressing HCT116 cells (C), OIPN as measured by VFH test (D), levels of total platinum in tumor samples (E) and DRG neurons (F) after completion of a 3-week treatment regimen. Bars and symbols represent mean ± SD. Details of the treatment and analysis are described in the Methods section (n=7-9). *P<0.05 vs vehicle control (C), vs oxaliplatin alone (D, F). NS, not statistically significant.